Richard I Shader

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3299967/richard-i-shader-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229 papers	12,603 citations	64 h-index	100 g-index
319 ext. papers	13,501 ext. citations	4.8 avg, IF	5.77 L-index

#	Paper	IF	Citations
229	James (Jeff) Walter Jefferson, MD. *Journal of Clinical Psychopharmacology*, **2021**, 41, 4	1.7	
228	Lung Cancer and Processing the Unknown: The Shoes of Damocles and 8 Coping Strategies. *Clinical Therapeutics*, **2021**, 43, 1432-1434	3.5	0
227	Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. *Journal of Clinical Pharmacology*, **2021**, 61, 193-203	2.9	1
226	COVID-19 and Depression. *Clinical Therapeutics*, **2020**, 42, 962-963	3.5	41
225	COVID-19, interferons, and depression: A commentary. *Psychiatry Research*, **2020**, 291, 113198	9.9	8
224	The problem of medical-psychiatric illness in the homeless and its occurrence in the midst of a viral pandemic: A commentary. *Psychiatry Research*, **2020**, 290, 113118	9.9	1
223	Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment. *Journal of Psychopharmacology*, **2019**, 33, 1340-1351	4.6	9
222	Psychosis and Psychotherapy. *Journal of Clinical Psychopharmacology*, **2019**, 39, 541-542	1.7	2
221	Risk Factors Versus Causes. *Journal of Clinical Psychopharmacology*, **2019**, 39, 293-294	1.7	2
220	Some Reflections on Meditation and Mindfulness. *Journal of Clinical Psychopharmacology*, **2017**, 37, 2-5	1.7	1
219	In Memorium-Martin M. Katz, PhD (1927-2017). *Journal of Clinical Psychopharmacology*, **2017**, 37, 122	1.7	
218	From disordered eating to addiction: the "food drug" in bulimia nervosa. *Journal of Clinical Psychopharmacology*, **2012**, 32, 376-89	1.7	40
217	Clinical Pharmacology and Therapeuticsof Antidepressants **2011**, 33-124		5
216	Mechanisms and Consequences of DrugDrug Interactions **2010**, 1		
215	The effect of chronic lorazepam administration in aging mice. *Brain Research*, **2006**, 1118, 13-24	3.7	5
214	Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. *Journal of Clinical Psychopharmacology*, **2005**, 25, 243-9	1.7	11
213	Looking Back and Looking Forward. *Journal of Clinical Psychopharmacology*, **2005**, 25, 1-2	1.7	

212	Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. *British Journal of Clinical Pharmacology*, **2005**, 60, 244-8	3.8	27
211	Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. *Clinical Pharmacology and Therapeutics*, **2004**, 76, 467-79	6.1	61
210	Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions. *Journal of Clinical Pharmacology*, **2004**, 44, 605-11	2.9	23
209	A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. *International Journal of Psychiatry in Medicine*, **2004**, 34, 103-23	1	38
208	Clinical Pharmacology and Therapeutics of Antidepressants **2004**, 33-117		4
207	The effect of age on sildenafil biotransformation in rat and mouse liver microsomes. *Drug Metabolism and Disposition*, **2003**, 31, 1306-9	4	12
206	Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. *Journal of Clinical Pharmacology*, **2003**, 43, 414-22	2.9	45
205	Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. *British Journal of Clinical Pharmacology*, **2003**, 56, 297-304	3.8	74
204	In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. *Drug Metabolism and Disposition*, **2002**, 30, 655-7	4	20
203	Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. *Journal of Clinical Pharmacology*, **2002**, 42, 1142-6	2.9	18
202	Pharmacokinetics of Protease Inhibitors and Drug Interactions with Psychoactive Drugs. *AIDS Prevention and Mental Health*, **2002**, 33-60		
201	Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. *British Journal of Pharmacology*, **2001**, 134, 1601-8	8.6	135
200	Pharmacodynamic and receptor binding changes during chronic lorazepam administration. *Pharmacology Biochemistry and Behavior*, **2001**, 69, 1-8	3.9	22
199	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. *Journal of Clinical Pharmacology*, **2001**, 41, 85-91	2.9	88
198	A benzodiazepine mood effect scale: reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. *American Journal of Drug and Alcohol Abuse*, **2001**, 27, 339-47	3.7	4
197	Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. *Journal of Clinical Pharmacology*, **2001**, 41, 1043-54	2.9	50
196	Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. *Critical Care Medicine*, **2000**, 28, 2750-7	1.4	32
195	Differential impairment of triazolam and zolpidem clearance by ritonavir. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2000**, 24, 129-36	3.1	43

194	Alprazolam-ritonavir interaction: implications for product labeling. *Clinical Pharmacology and Therapeutics*, **2000**, 67, 335-41	6.1	94
193	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2000**, 24, 129-136	3.1	59
192	In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. *Biological Psychiatry*, **2000**, 47, 655-61	7.9	50
191	Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. *Journal of Clinical Psychopharmacology*, **2000**, 20, 338-46	1.7	11
190	In situ hybridization histochemistry as a method to assess GABA(A) receptor subunit mRNA expression following chronic alprazolam administration. *Journal of Psychopharmacology*, **1999**, 13, 211-8	4.6	7
189	Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. *British Journal of Clinical Pharmacology*, **1999**, 48, 89-97	3.8	123
188	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. *Psychopharmacology*, **1999**, 145, 113-22	4.7	66
187	Lorazepam attenuates the behavioral effects of dizocilpine. *Pharmacology Biochemistry and Behavior*, **1999**, 62, 103-10	3.9	10
186	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. *Neuropsychopharmacology*, **1999**, 20, 480-90	8.7	129
185	Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. *Biopharmaceutics and Drug Disposition*, **1999**, 20, 385-8	1.7	26
184	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. *Biological Psychiatry*, **1999**, 46, 839-49	7.9	69
183	Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. *Drug Metabolism Reviews*, **1999**, 31, 545-60	7	29
182	Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. *Journal of Clinical Pharmacology*, **1999**, 39, 775-85	2.9	35
181	Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. *Journal of Clinical Psychopharmacology*, **1999**, 19, 23S-35S	1.7	71
180	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. *Journal of Pharmacy and Pharmacology*, **1998**, 50, 265-74	4.8	35
179	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. *Journal of Pharmacy and Pharmacology*, **1998**, 50, 997-1004	4.8	78
178	Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 661-71	6.1	73
177	Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 553-61	6.1	107

176	Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 237-47	6.1	103
175	Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. *Clinical Pharmacology and Therapeutics*, **1998**, 64, 278-85	6.1	83
174	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. *Journal of Pharmaceutical Sciences*, **1998**, 87, 1184-9	3.9	53
173	Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. *Psychopharmacology*, **1998**, 140, 293-9	4.7	16
172	Cytochromes: a primer for child and adolescent psychiatrists. *Journal of the American Academy of Child and Adolescent Psychiatry*, **1998**, 37, 447-50	7.2	10
171	In vitro approaches to predicting drug interactions in vivo. *Biochemical Pharmacology*, **1998**, 55, 113-22	6	176
170	Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. *Journal of Clinical Pharmacology*, **1998**, 38, 603-9	2.9	36
169	Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. *Journal of Clinical Pharmacology*, **1998**, 38, 112-21	2.9	125
168	Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. *Journal of Clinical Pharmacology*, **1998**, 38, 14-21	2.9	23
167	Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. *Journal of Clinical Pharmacology*, **1998**, 38, 106-11	2.9	193
166	Alprazolam is another substrate for human cytochrome P450-3A isoforms. *Journal of Clinical Psychopharmacology*, **1998**, 18, 256	1.7	29
165	Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. *Journal of Clinical Psychopharmacology*, **1998**, 18, 338-41	1.7	12
164	Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. *Journal of Clinical Pharmacology*, **1997**, 37, 437-41	2.9	8
163	Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. *Journal of Clinical Pharmacology*, **1997**, 37, 64-73	2.9	17
162	Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors. *Journal of Clinical Pharmacology*, **1997**, 37, 193-200	2.9	32
161	Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. *Journal of Clinical Pharmacology*, **1997**, 37, 693-703	2.9	228
160	Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. *Biological Psychiatry*, **1997**, 41, 377-80	7.9	24
159	Human cytochromes mediating N-demethylation of fluoxetine in vitro. *Psychopharmacology*, **1997**, 132, 402-7	4.7	60

158	Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. *British Journal of Clinical Pharmacology*, **1997**, 44, 495-8	3.8	70
157	Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. *Biopharmaceutics and Drug Disposition*, **1997**, 18, 139-49	1.7	6
156	Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. *Biopharmaceutics and Drug Disposition*, **1997**, 18, 213-26	1.7	89
155	Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. *Biopharmaceutics and Drug Disposition*, **1997**, 18, 227-40	1.7	62
154	Can you provide a table of equivalences for benzodiazepines and other marketed benzodiazepine receptor agonists?. *Journal of Clinical Psychopharmacology*, **1997**, 17, 331	1.7	8
153	Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. *Journal of Clinical Pharmacology*, **1996**, 36, 792-8	2.9	45
152	Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. *Journal of Clinical Pharmacology*, **1996**, 36, 783-91	2.9	166
151	Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. *Psychopharmacology*, **1996**, 128, 398-407	4.7	90
150	Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. *British Journal of Clinical Pharmacology*, **1996**, 41, 339-43	3.8	39
149	Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. *British Journal of Clinical Pharmacology*, **1996**, 41, 593-604	3.8	29
148	Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. *Pharmacology*, **1996**, 52, 125-34	2.3	39
147	Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. *Journal of Clinical Psychopharmacology*, **1996**, 16, 104-12	1.7	63
146	Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. *Clinical Pharmacokinetics*, **1995**, 29 Suppl 1, 33-43; discussion 43-4	6.2	89
145	Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. *Journal of Clinical Psychopharmacology*, **1995**, 15, 125-31	1.7	140
144	A white paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics. *Journal of Clinical Pharmacology*, **1994**, 34, 812-5	2.9	1
143	Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. *Clinical Pharmacology and Therapeutics*, **1994**, 56, 100-11	6.1	54
142	In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. *Journal of Clinical Pharmacology*, **1994**, 34, 1222-7	2.9	86
141	Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. *Clinical Pharmacokinetics*, **1993**, 24, 141-60	6.2	35

140	Use of benzodiazepines in anxiety disorders. *New England Journal of Medicine*, **1993**, 328, 1398-405	59.2	255
139	Chronic benzodiazepine administration. XI. Concurrent administration of PK11195 attenuates lorazepam discontinuation effects. *Neuropsychopharmacology*, **1993**, 8, 267-73	8.7	15
138	Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. *Pharmacology*, **1993**, 47, 268-76	2.3	84
137	Possible interaction between fluoxetine and pimozide causing sinus bradycardia. *Canadian Journal of Psychiatry*, **1993**, 38, 62-3	4.8	48
136	A patient of mine had problems of nausea, bloating, and diarrhea after taking fluoxetine for two months at 20 mg/day. A similar problem occurred when sertraline at 50 mg/day was tried. I have read that similar problems occur with paroxetine and fluvoxamine. What is the basis for this?. *Journal of Clinical Psychopharmacology*, **1993**, 13, 79	1.7	2
135	Clinical Uses of Benzodiazepines. *Journal of Clinical Psychopharmacology*, **1993**, 13, 2S	1.7	56
134	Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam. *Psychopharmacology*, **1993**, 111, 91-5	4.7	14
133	A patient of mine missed a period while taking fluoxetine; it turned out that she was not pregnant. However, the question arose about the safety of fluoxetine during pregnancy. What is known?. *Journal of Clinical Psychopharmacology*, **1992**, 12, 213	1.7	3
132	Appropriate use and regulatory control of benzodiazepines. *Journal of Clinical Pharmacology*, **1991**, 31, 781-4	2.9	31
131	Modification of gamma-aminobutyric acidA receptor binding and function by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vitro and in vivo: effects of aging. *Journal of Neurochemistry*, **1991**, 56, 1241-7	6	19
130	Chronic benzodiazepine administration. VII. Behavioral tolerance and withdrawal and receptor alterations associated with clonazepam administration. *Psychopharmacology*, **1991**, 104, 225-30	4.7	30
129	Sensitivity to triazolam in the elderly. *New England Journal of Medicine*, **1991**, 324, 1691-8	59.2	234
128	Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). *Clinical Pharmacokinetics*, **1991**, 21, 165-77	6.2	140
127	Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II). *Clinical Pharmacokinetics*, **1991**, 21, 262-73	6.2	70
126	Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine. *Biochemical Pharmacology*, **1991**, 42 Suppl, S99-104	6	8
125	Greetings on Our 10th and a Commentary on Redundancy in Publication. *Journal of Clinical Psychopharmacology*, **1990**, 10, 1-2	1.7	2
124	The relationship of alprazolam dose to steady-state plasma concentrations. *Journal of Clinical Psychopharmacology*, **1990**, 10, 27-32	1.7	28
123	The neuropsychiatric effects of aspartame in normal volunteers. *Journal of Clinical Pharmacology*, **1990**, 30, 454-60	2.9	22

122	Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. *Journal of Clinical Psychopharmacology*, **1990**, 10, 48-50	1.7	90
121	Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. *Biomedical Applications*, **1990**, 534, 202-7		18
120	Benzodiazepine discontinuation syndromes. *Journal of Psychiatric Research*, **1990**, 24 Suppl 2, 73-9	5.2	28
119	Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. *Psychopharmacology*, **1990**, 101, 539-44	4.7	12
118	Chronic morphine administration augments benzodiazepine binding and GABAA receptor function. *Psychopharmacology*, **1990**, 101, 545-9	4.7	29
117	The diagnosis and treatment of panic disorder in alcoholics: three cases. *American Journal of Drug and Alcohol Abuse*, **1990**, 16, 287-95	3.7	9
116	Chronic administration of benzodiazepines--V. Rapid onset of behavioral and neurochemical alterations after discontinuation of alprazolam. *Neuropharmacology*, **1990**, 29, 237-41	5.5	26
115	Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABAA-receptor function. *British Journal of Pharmacology*, **1990**, 101, 839-42	8.6	23
114	Caffeine-induced behavioural stimulation is dose- and concentration-dependent. *British Journal of Pharmacology*, **1990**, 100, 435-40	8.6	21
113	Bioinequivalence of a generic brand of diazepam. *Biopharmaceutics and Drug Disposition*, **1989**, 10, 597-605	1.7	11
112	Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. *Clinical Pharmacology and Therapeutics*, **1989**, 45, 356-65	6.1	147
111	Chronic benzodiazepine administration. IV. Rapid development of tolerance and receptor downregulation associated with alprazolam administration. *Biochemical Pharmacology*, **1989**, 38, 3773-76		52
110	Lorazepam discontinuation promotes inverse agonist effects of benzodiazepines. *British Journal of Pharmacology*, **1989**, 98, 451-4	8.6	19
109	Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women. *Clinical Pharmacokinetics*, **1989**, 16, 312-6	6.2	23
108	Implications of altered drug disposition in the elderly: studies of benzodiazepines. *Journal of Clinical Pharmacology*, **1989**, 29, 866-72	2.9	83
107	Dr. Ciraulo and Associates Reply. *American Journal of Psychiatry*, **1989**, 146, 572-a-572	11.9	21
106	Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. *Pharmacology*, **1989**, 38, 327-34	2.3	27
105	Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. *Clinical Pharmacology and Therapeutics*, **1988**, 44, 326-34	6.1	69

104	Low-dose alprazolam augments motor activity in mice. *Pharmacology Biochemistry and Behavior*, **1988**, 30, 511-3	3.9	23
103	Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. *Journal of Clinical Pharmacology*, **1988**, 28, 853-9	2.9	31
102	Alprazolam pharmacokinetics in women on low-dose oral contraceptives. *Journal of Clinical Pharmacology*, **1988**, 28, 454-7	2.9	22
101	Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. *Journal of Clinical Pharmacology*, **1988**, 28, 228-33	2.9	17
100	Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. *New England Journal of Medicine*, **1987**, 317, 722-8	59.2	83
99	Alprazolam Kinetics Following Sublingual and Oral Administration. *Journal of Clinical Psychopharmacology*, **1987**, 7, 332???334	1.7	15
98	Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. *Brain Research*, **1987**, 414, 395-400	3.7	108
97	Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods. *Biomedical Applications*, **1987**, 422, 274-80		17
96	Benzodiazepine receptor binding: influence of physiologic and pharmacologic factors. *Biopharmaceutics and Drug Disposition*, **1987**, 8, 103-14	1.7	23
95	Trazodone kinetics: effect of age, gender, and obesity. *Clinical Pharmacology and Therapeutics*, **1987**, 42, 193-200	6.1	102
94	Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. *Clinical Pharmacology and Therapeutics*, **1987**, 41, 562-70	6.1	43
93	Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. *Journal of Neurochemistry*, **1987**, 49, 1595-601	6	28
92	Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. *Journal of Clinical Pharmacology*, **1986**, 26, 299-303	2.9	26
91	Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. *Arthritis and Rheumatism*, **1986**, 29, 971-80		39
90	Sedative effects and impaired learning and recall after single oral doses of lorazepam. *Clinical Pharmacology and Therapeutics*, **1986**, 39, 526-9	6.1	48
89	Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. *Journal of Clinical Pharmacology*, **1986**, 26, 529-33	2.9	77
88	Age, sex, and nitrazepam kinetics: relation to antipyrine disposition. *Clinical Pharmacology and Therapeutics*, **1985**, 38, 697-703	6.1	35
87	Tissue distribution of diazepam and its metabolite desmethyldiazepam: a human autopsy study. *Journal of Clinical Pharmacology*, **1985**, 25, 613-5	2.9	16

86	Benzodiazepine drug-drug interactions commonly occurring in clinical practice. *Current Medical Research and Opinion*, **1984**, 8 Suppl 4, 80-93	2.5	17
85	Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. *Clinical Pharmacology and Therapeutics*, **1984**, 35, 348-53	6.1	34
84	Absorption and disposition of ibuprofen in the elderly. *Arthritis and Rheumatism*, **1984**, 27, 1066-9		61
83	Noninteraction of temazepam and cimetidine. *Journal of Pharmaceutical Sciences*, **1984**, 73, 399-401	3.9	14
82	Absolute bioavailability of imipramine: influence of food. *Psychopharmacology*, **1984**, 83, 104-6	4.7	20
81	The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. *Clinical Pharmacokinetics*, **1984**, 9, 177-83	6.2	67
80	Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. *Journal of Clinical Pharmacology*, **1984**, 24, 187-93	2.9	18
79	Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. *Journal of Clinical Pharmacology*, **1984**, 24, 255-63	2.9	15
78	Effect of Age, Gender, and Obesity on Midazolam Kinetics. *Anesthesiology*, **1984**, 61, 27-35	4.3	469
77	Halazepam as a precursor of desmethyldiazepam: quantitation by electron-capture gas-liquid chromatography. *Psychopharmacology*, **1983**, 80, 178-80	4.7	9
76	Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. *Psychopharmacology*, **1983**, 80, 275-8	4.7	64
75	Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. *Drug Metabolism Reviews*, **1983**, 14, 251-92	7	93
74	Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. *Clinical Pharmacokinetics*, **1983**, 8, 83-94	6.2	30
73	Clinical pharmacokinetics of the newer benzodiazepines. *Clinical Pharmacokinetics*, **1983**, 8, 233-52	6.2	101
72	Antipyretic analgesic drugs as models for studies of drug disposition in old age. *American Journal of Medicine*, **1983**, 75, 127-32	2.4	10
71	Drug therapy. Current status of benzodiazepines. *New England Journal of Medicine*, **1983**, 309, 354-8	59.2	255
70	Absolute Bioavailability of Oral and Intramuscular Diazepam. *Anesthesia and Analgesia*, **1983**, 62, 1???8	3.9	72
69	Drug therapy. Current status of benzodiazepines. *New England Journal of Medicine*, **1983**, 309, 410-6	59.2	215

68	Prolonged accumulation of diazepam in obesity. *Journal of Clinical Pharmacology*, **1983**, 23, 369-76	2.9	57
67	Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. *Clinical Pharmacology and Therapeutics*, **1983**, 33, 628-32	6.1	47
66	Drug therapy: drug disposition in old age. *New England Journal of Medicine*, **1982**, 306, 1081-8	59.2	541
65	Clobazam kinetics: intrasubject variability and effect of food on adsorption. *Journal of Clinical Pharmacology*, **1982**, 22, 69-73	2.9	39
64	Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. *Journal of the American Geriatrics Society*, **1982**, 30, 684-9	5.6	28
63	Panic disorders: current perspectives. *Journal of Clinical Psychopharmacology*, **1982**, 2, 2S-10S	1.7	22
62	Benzodiazepine hypnotics: kinetic and therapeutic options. *Sleep*, **1982**, 5 Suppl 1, S18-27	1.1	40
61	Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. *Journal of Pharmaceutical Sciences*, **1982**, 71, 248-52	3.9	93
60	Tricyclic antidepressant determination in human plasma by gas-liquid chromatography using nitrogen-phosphorous detection: application to single-dose pharmacokinetic studies. *Pharmacology* , **1981**, 23, 57-63	2.3	21
59	Effect of age and gender on disposition of temazepam. *Journal of Pharmaceutical Sciences*, **1981**, 70, 1104-7	3.9	130
58	Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. *Biomedical Applications*, **1981**, 225, 202-7		74
57	Benzodiazepine overdosage: plasma concentrations and clinical outcome. *Psychopharmacology*, **1981**, 73, 381-3	4.7	29
56	Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. *Psychopharmacology*, **1981**, 75, 193-7	4.7	57
55	Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. *Clinical Pharmacology and Therapeutics*, **1981**, 30, 475-86	6.1	151
54	Desmethyldiazepam kinetics in the elderly after oral prazepam. *Clinical Pharmacology and Therapeutics*, **1980**, 28, 196-202	6.1	82
53	Diazepam disposition determinants. *Clinical Pharmacology and Therapeutics*, **1980**, 27, 301-12	6.1	319
52	The effects of antianxiety and antipsychotic drugs and sexual behavior. *Modern Problems of Pharmacopsychiatry*, **1980**, 15, 91-110		12
51	Self-rated sedation and plasma concentrations of desmethyldiazepam following single doses of clorazepate. *Psychopharmacology*, **1979**, 66, 289-90	4.7	19

50	Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. *Journal of Pharmacokinetics and Pharmacodynamics*, **1979**, 7, 159-79		30
49	Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. *Clinical Pharmacology and Therapeutics*, **1979**, 26, 449-56	6.1	25
48	Lorazepam kinetics in the elderly. *Clinical Pharmacology and Therapeutics*, **1979**, 26, 103-13	6.1	123
47	Single-dose kinetics of prazepam, a precursor of desmethyldiazepam. *Journal of Clinical Pharmacology*, **1979**, 19, 445-50	2.9	11
46	Overdosage with pentobarbital and secobarbital: assessment of factors related to outcome. *Journal of Clinical Pharmacology*, **1979**, 19, 758-68	2.9	15
45	Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. *Journal of Pharmaceutical Sciences*, **1979**, 68, 57-63	3.9	156
44	Benzodiazepines: some aspects of their clinical pharmacology. *Novartis Foundation Symposium*, **1979**, 141-55		4
43	Absorption of oral and intramuscular chlordiazepoxide. *European Journal of Clinical Pharmacology*, **1978**, 13, 267-74	2.8	26
42	Effect of a cocktail on diazepam absorption. *Psychopharmacology*, **1978**, 57, 199-203	4.7	33
41	Analysis of lorazepam and its glucoronide metabolite by electron-capture gas–liquid chromatography. *Biomedical Applications*, **1978**, 146, 311-320		76
40	Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. *Drug Metabolism Reviews*, **1978**, 8, 13-28	7	199
39	Clinical pharmacokinetics of chlordiazepoxide. *Clinical Pharmacokinetics*, **1978**, 3, 381-94	6.2	47
38	Drug interactions involving psychotropic drugs. *Psychosomatics*, **1978**, 19, 671-3, 677-81	2.6	9
37	Depression in the elderly. I. Relationship between depression, psychologic defense mechanisms and physical illness. *Journal of the American Geriatrics Society*, **1978**, 26, 253-60	5.6	80
36	Pharmacokinetic understanding of antianxiety drug therapy. *Southern Medical Journal*, **1978**, 71 Suppl 2, 2-9	0.6	31
35	Effect of abdominal radiation therapy on drug absorption in humans. *Journal of Clinical Pharmacology*, **1978**, 18, 388-96	2.9	11
34	Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. *Clinical Pharmacology and Therapeutics*, **1978**, 24, 308-15	6.1	54
33	Depression in the elderly. II. Possible drug etiologies; differential diagnostic criteria. *Journal of the American Geriatrics Society*, **1978**, 26, 303-8	5.6	17

32	Diazepam absorption: effect of antacids and food. *Clinical Pharmacology and Therapeutics*, **1978**, 24, 600-9	6.1	62
31	Acute overdosage with benzodiazepine derivatives. *Clinical Pharmacology and Therapeutics*, **1977**, 21, 497-514	6.1	99
30	Toxicity of high-dose flurazepam in the elderly. *Clinical Pharmacology and Therapeutics*, **1977**, 21, 355-61	6.1	183
29	Clinical pharmacokinetics of lorazepam. II. Intramuscular injection. *Clinical Pharmacology and Therapeutics*, **1977**, 21, 222-30	6.1	43
28	Kinetics of intravenous chlordiazepoxide: sex differences in drug distribution. *Clinical Pharmacology and Therapeutics*, **1977**, 22, 893-903	6.1	34
27	Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results. *Journal of Clinical Pharmacology*, **1977**, 17, 490-4	2.9	28
26	Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. *Journal of Clinical Pharmacology*, **1977**, 17, 709-18	2.9	86
25	The Council on Medical Education and Career Development. *American Journal of Psychiatry*, **1977**, 134, 477-480	11.9	19
24	Clinical pharmacokinetics of lorazepam. IV. Long-term oral administration. *Journal of Clinical Pharmacology*, **1977**, 17, 495-500	2.9	9
23	Factors influencing blood concentrations of chlordiazepoxide: a use of multiple regression analysis. *Psychopharmacology*, **1977**, 54, 277-82	4.7	16
22	Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. *Clinical Pharmacology and Therapeutics*, **1976**, 20, 329-41	6.1	66
21	Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients. *Clinical Pharmacology and Therapeutics*, **1976**, 20, 571-8	6.1	17
20	Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. *Clinical Pharmacology and Therapeutics*, **1976**, 19, 234-9	6.1	42
19	Serum creatine phosphokinase concentrations after intramuscular chlordiazepoxide and its solvent. *Journal of Clinical Pharmacology*, **1976**, 16, 118-21	2.9	15
18	Psychopharmacologic investigations in healthy elderly volunteers: effects of pipradrol-vitamin (Alertonic) elixir and placebo in relation to research design. *Journal of the American Geriatrics Society*, **1975**, 23, 277-9	5.6	6
17	Flurazepam hydrochloride. *Clinical Pharmacology and Therapeutics*, **1975**, 17, 1-14	6.1	50
16	Psychopharmacologic investigations in elderly volunteers: Effect of diazepam in males. *Journal of the American Geriatrics Society*, **1975**, 23, 451-7	5.6	20
15	Psychopharmacologic investigations in healthy elderly volunteers: MMPI depression scale. *Journal of the American Geriatrics Society*, **1975**, 23, 350-4	5.6	13

14	Rational Use of psychotropic drugs IV. Antidepressants. *American Journal of Health-System Pharmacy*, **1975**, 32, 59-64	2.2	
13	Social adjustment and psychopathology among formerly hospitalized and non-hospitalized mothers. I. Development of the social role adjustment instrument. *Journal of Psychiatric Research*, **1975**, 12, 1-18	5.2	71
12	Social role performance and psychopathology among recently hospitalized and nonhospitalized mothers. II. Correlates with life stress and self-reported psychopathology. *Journal of Nervous and Mental Disease*, **1974**, 159, 81-90	1.8	10
11	Pharmacokinetic Determinants of the Response to Single Doses of Chlordiazepoxide. *American Journal of Psychiatry*, **1974**, 131, 1395-1397	11.9	2
10	Drug therapy. Benzodiazepines (first of two parts). *New England Journal of Medicine*, **1974**, 291, 1011-5	59.2	114
9	Rating scales for psychotropic drug research with geriatric patients. I. Behavior ratings. *Journal of the American Geriatrics Society*, **1972**, 20, 209-14	5.6	13
8	Rating scales for psychotropic drug research with geriatric patients. II. Mood ratings. *Journal of the American Geriatrics Society*, **1972**, 20, 215-21	5.6	18
7	Sexual dysfunction associated with mesoridazine besylate (serentil). *Psychopharmacology*, **1972**, 27, 293-4	4.7	14
6	Meprobamate: a study of irrational drug use. *American Journal of Psychiatry*, **1971**, 127, 1297-303	11.9	30
5	Chlordiazepoxide, expectation and hostility. *Psychopharmacology*, **1969**, 14, 38-45	4.7	25
4	The observers and the observed: the effects of doing ratings on staff-patient contact patterns. *Journal of Consulting Psychology*, **1966**, 30, 456-7		1
3	SEXUAL DYSFUNCTION ASSOCIATED WITH THIORIDAZINE HYDROCHLORIDE. *JAMA - Journal of the American Medical Association*, **1964**, 188, 1007-9	27.4	26
2	The Use of Generic Drugs in Pediatric Psychopharmacology39-50		
1	Mechanisms and Consequences of DrugDrug Interactions879-917		7